Content about John Castellani

March 25, 2013
Drug makers ramp up treatments for chronic conditions in the elderly, PhRMA report finds

More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

WASHINGTON — More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

November 29, 2012
PhRMA: More than 70 drugs, vaccines under development for HIV/AIDS

Drug companies have made "remarkable progress" in treatment options for patients with HIV and AIDS, according to two new reports from a drug industry trade group.

WASHINGTON — Drug companies have made "remarkable progress" in treatment options for patients with HIV and AIDS, according to two new reports from a drug industry trade group.

November 29, 2012
User fee re-authorization 
fuels generics’ outlook

Generic Pharmaceutical Association president and CEO Ralph Neas called it “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act.” John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, said the law served “the best interests of America’s patients.”


Generic Pharmaceutical Association president and CEO Ralph Neas called it “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act.” John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, said the law served “the best interests of America’s patients.”


September 28, 2012
Health, industry officials look for ways to combat counterfeit drug spread

Keynote speeches by pharmaceutical industry and regulatory leaders got top billing as more than 140 government, healthcare industry, law enforcement and patient advocacy officials gathered to find ways to combat the spread of counterfeit medicines.

WASHINGTON — Keynote speeches by pharmaceutical industry and regulatory leaders got top billing as more than 140 government, healthcare industry, law enforcement and patient advocacy officials gathered to find ways to combat the spread of counterfeit medicines.

July 30, 2012
Mental health, medicines 
top of mind for industry

In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.


July 13, 2012
PhRMA: More than 100 drugs under development for mental illnesses

Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest lobbying group for the drug industry said Thursday.

WASHINGTON — Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest trade group for the drug industry said Thursday.

The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.

October 11, 2011
PhRMA: 900+ biotech drugs in development

Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.


WASHINGTON — Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.


December 22, 2010
PhRMA expands board of directors

The Pharmaceutical Research and Manufacturers of America has added four new members to its board.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America has added four new members to its board.

Joining PhRMA are Ian Read, Pfizer's president and CEO; Jerzy Gruhn, Novo Nordisk president; Mark Iwicki, Sunovion Pharmaceuticals president and COO; and Staffan Schuberg, Lundbeck president.

October 10, 2010
Drug makers fight infectious diseases with 400 drugs in pipeline

Humanity has come a long way since the days when people thought sickness came from...

July 15, 2010
Castellani successfully can fill Tauzin's shoes

It’s been said many times that the people you know are as important as what...

WHAT IT MEANS AND WHY IT'S IMPORTANT It’s been said many times that the people you know are as important as what you know. In the case of Billy Tauzin, former president and CEO of the Pharmaceutical Research and Manufacturers of America, this adage was especially true, considering his former career as a member of Congress.

(THE NEWS: PhRMA names new president, CEO. For the full story, click here)